Bone Cancer Stage IA (Enneking I, intracompartmental)

Reviewed by Oncology Team, HealOnco | Last updated: 2026-04

5-year survival 90%+ (rarely reached in aggressive tumors like osteosarcoma or Ewing sarcoma; more common in giant cell tumors and low-grade chondrosarcoma).

5-year survival rate

Stage IA (Enneking I, intracompartmental)

Tumor confined within anatomic compartment of origin; low-grade or small size. No breakthrough cortex, no soft-tissue…

What Stage IA (Enneking I, intracompartmental) Means

Tumor confined within anatomic compartment of origin; low-grade or small size. No breakthrough cortex, no soft-tissue mass.

Treatment Approach for Stage IA (Enneking I, intracompartmental)

Surgical resection with wide margins (limb-salvage surgery). Adjuvant chemotherapy based on histology and grade.

Survival Rates and Prognosis

The 5-year survival rate for bone cancer at Stage IA (Enneking I, intracompartmental) is approximately 5-year survival 90%+ (rarely reached in aggressive tumors like osteosarcoma or Ewing sarcoma; more common in giant cell tumors and low-grade chondrosarcoma).. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.

Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.

How Other Stages Compare

Stage	5-Year Survival	Treatment
Stage IB (Enneking II, extracompartmental)	5-year survival 60-75% with multimodal therapy (chemotherapy + surgery for osteosarcoma/Ewing sarcoma).	Neoadjuvant chemotherapy (MAP protocol for osteosarcoma; VIDE/VAC or similar…
Stage III (Metastatic at Diagnosis)	5-year survival 20-50% (historically poor, improving with aggressive multiagent chemotherapy and metastatectomy protocols). Prognosis depends on number, size, and resectability of metastases.	Intensive multiagent neoadjuvant chemotherapy (osteosarcoma: MAP with possible…
Recurrent Disease	5-year survival 10-30% depending on site and timing of recurrence. Early recurrence (within 1-2 years) indicates aggressive biology; late recurrence may respond to re-treatment.	Re-staging and assessment of chemotherapy sensitivity. Options include…